Organization
QuintilesIMS, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
QuintilesIMS, Inc.
... for the most recent twelve months ended in September 2017, according to IMS Health*. Dr. Reddy's Laboratories' Clofarabine Injection is available in single-dose, 20 mL ...
... the merger of Quintiles Transnational Holdings Inc. and IMS Health Holdings, Inc., QuintilesIMS's approximately 50,000 employees conduct operations in more than 100 countries. Companies seeking ...
... to Q3 2016 based on data from both Symphony Health Solutions and QuintilesIMS. R&D progress: REDUCE-IT, Amarin's potential landmark long-term cardiovascular outcomes study, progressing towards ...
... today results of a nationwide survey conducted among 202 U.S. gastroenterologists by QuintilesIMS using its ProVoice survey methodology. For the third consecutive year, IBgard® continues ...
... drug-free, non-prescription sleep brand, revealed results of a nationwide survey conducted by QuintilesIMS among 700 U.S. primary care physicians with certification in sleep disorders. REMfresh® ...
... There are more than 1,100 CRO companies around the world, led by QuintilesIMS, Covance, inVentiv Health, Charles River, Parexel, PPD, ICON and WuXi AppTec. Global ...
... Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE:Q) will announce its third-quarter 2017 financial results before the ...
... Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE:Q) will host an Analyst and Investor Conference in New ...
... $3.64 billion for the 12 months ending July 31, 2017, according to QuintilesIMS. Approximately 400,000 individuals in the U.S. have MS and relapsing MS accounts ...
... for the most recent twelve months ending in July 2017 according to IMS Health*. Dr. Reddy's Sevelamer Carbonate Tablets, 800 mg are available in the ...
... 346.9 million for the 12 months ending July 31, 2017, according to QuintilesIMS Health. Currently, Mylan has 225 ANDAs pending FDA approval representing approximately $ ...
... Quintiles IMS Holdings, Inc. ("QuintilesIMS") (NYSE: Q) announced today the launch of an underwritten, secondary ...
... $346.9 million for the 12 months ending July 31, 2017, according to QuintilesIMS Health. Currently, Mylan has 225 ANDAs pending FDA approval representing approximately $101 ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤